The global oncology biosimilars market is witnessing rapid expansion, driven by the increasing burden of cancer worldwide and the need for cost-effective treatment alternatives. Biosimilars, which are highly similar to already approved biologic drugs, offer comparable safety, efficacy, and quality at reduced costs. As healthcare systems face rising financial pressure, biosimilars are emerging...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek